Aims: To compare insulin sensitivity, β-cell function and iron status biomarkers in non-transfusion-dependent thalassaemia (NTDT) with iron excess during pre- and post-iron chelation. Methods: Subjects with NTDT, aged older than 10 years, with serum ferritin >300 ng/ml, were included. Iron chelation with deferasirox (10 mg/kg/day) was prescribed daily for 6 months. Results: Ten patients with a median age of 17.4 years were enrolled. The comparison between pre- and post-chelation demonstrated significantly lower iron load: median serum ferritin (551.4 vs. 486.2 ng/ml, p = 0.047), median TIBC (211.5 vs. 233.5 µg/dl, p = 0.009) and median non-transferrin binding iron (5.5 vs. 1.4 µM, p = 0.005). All patients had a normal oral glucose tolerance test (OGTT) both pre- and post-chelation. However, fasting plasma glucose was significantly reduced after iron chelation (85.0 vs.79.5 mg/dl, p = 0.047). MRI revealed no significant changes of iron accumulation in the heart and liver after chelation, but there was a significantly lower iron load in the pancreas, assessed by higher T2* at post-chelation compared with pre-chelation (41.9 vs. 36.7 ms, p = 0.047). No adverse events were detected. Conclusions: A trend towards improving insulin sensitivity and β-cell function as well as a reduced pancreatic iron load was observed following 6 months of iron chelation (TCTR20160523003).

Tanphaichitr VS: Current situation of thalassemia in Thailand. The 7th International Conference on Thalassemia and Hemoglobinopathies. Bangkok, Ministry of Public Health, Thailand, 1999, pp 78-79.
Musallam KM, Cappellini MD, Wood JC, Taher AT: Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev 2012;26(suppl 1):16-19.
Pippard MJ, Callender ST, Warner GT, Weatherall DJ: Iron absorption and loading in β-thalassaemia intermedia. Lancet 1979;2:819-821.
Brittenham GM: The red cell cycle; in Brock JH, Halliday JW, Pippard MJ, Powell LW (eds): Iron Metabolism in Health and Disease. London, Saunders, 1994.
Zhao Z, Li Z, Liu G, Yan F, Ma X, Huang Z, Tian H: Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis. PLoS One 2012;7:e41641.
Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, Cooksey RC, Gabrielsen D, Adams TD, Hunt SC, Hopkins PN, Cefalu WT, McClain DA: Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest 2012;122:3529-3540.
Tajima S, Ikeda Y, Sawada K, Yamano N, Horinouchi Y, Kihira Y, Ishizawa K, Izawa-Ishizawa Y, Kawazoe K, Tomita S, Minakuchi K, Tsuchiya K, Tamaki T: Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab 2012;302:E77-E86.
Taher AT, Musallam KM, El-Beshlawy A, Karimi M, Daar S, Belhoul K, Saned MS, Graziadei G, Cappellini MD: Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol 2010; 150:486-489.
Cario H, Holl RW, Debatin KM, Kohne E: Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatr 2003;162:139-146.
Singh S, Hider RC, Porter J: A direct method for quantification of non-transferrin-bound iron. Anal Biochem 1990;1:320-323.
Kattamis C, Ladis V, Tsoussis D, Kaloumenou I, Theodoridis C: Evolution of glucose intolerance and diabetes in transfused patients with thalassemia. Pediatr Endocrinol Rev 2004;2(suppl):267-271.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470.
Seltzer HS, Allen EW, Herron AL Jr, Brennan MT: Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967;46:323-335.
Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ: Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 2006;9:1388-1391.
Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ: Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart 2001;22:2171-2179.
Sripichai O, Makarasara W, Munkongdee T, Kumkhaek C, Nuchprayoon I, Chuansumrit A, Chuncharunee S, Chantrakoon N, Boonmongkol P, Winichagoon P, Fucharoen S: A scoring system for the classification of beta-thalassemia/Hb E disease severity. Am J Hematol 2008;83:482-484.
Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V; Thalassemia International Federation: Guidelines for the management of non-transfusion dependent thalassemia (NTDT). Nicosia, Team Up Creations Ltd, 2013, pp 43-44.
Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD: Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassemia. Br J Haematol 2015;168:284-290.
Olsson KS, Eriksson K, Ritter B, Heedman PA: Screening for iron overload using transferrin saturation. Acta Med Scand 1984;215:105-112.
Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD: Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012;120:970-977.
Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ: Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*. Toxicol Mech Methods 2013;23:48-56.
Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH: Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med 2006;84:349-364.
Au WY, Lam WW, Chu W, Tam S, Wong WK, Liang R, Ha SY: A T2* magnetic resonance imaging study of pancreas iron overload in thalassemia major. Haematologica 2008;93:116-119.
Noetzli LJ, Papudesi J, Coates TD, Wood JC: Pancreatic iron loading predicts cardiac iron loading in thalassemia. Blood 2009;114:4021-4026.
Fernandez-Real JM, Lupez-Bermejo A, Ricart W: Cross-talk between iron metabolism and diabetes. Diabetes 2002;51:2348-2354.
Cheng K, Ho K, Stokes R, Scott C, Lau SM, Hawthorne WJ, O'Connell PJ, Loudovaris T, Kay TW, Kulkarni RN, Okada T, Wang XL, Yim SH, Shah Y, Grey ST, Biankin AV, Kench JG, Laybutt DR, Gonzalez FJ, Kahn CR, Gunton JE: Hypoxia-inducible factor-1 alpha regulates beta cell function in mouse and human islets. J Clin Invest 2010;120:2171-2183.
Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB: Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004;29:711-717.
Breuer W, Hershko C, Cabantchik ZI: The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000;23:185-192.
Taher A, Musallam KM, El Rassi F, Duca L, Inati A, Koussa S, Cappellini MD: Levels of non-transferrin bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 2009;146:569-572.
Fargnoli JL, Fung TT, Olenczuk DM, Chamberland JP, Hu FB, Mantzoros CS: Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study. Am J Clin Nutr 2008;88:1213-1224.
Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, Cooksey RC, Gabrielsen D, Adams TD, Hunt SC, Hopkins PN, Cefalu WT, McClain DA: Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest 2012;122:3529-3540.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.